We identified regulator of G-protein signaling-5 (RGS-5) as an angiogenic pericyte marker at sites of physiological and pathological angiogenesis. In a mouse model of pancreatic islet cell carcinogenesis, RGS-5 is specifically induced in the vasculature of premalignant lesions during the "angiogenic switch", and further elevated in tumor vessels. Similarly, RGS-5 is overexpressed in highly angiogenic astrocytomas but not in hypoxia-inducible factor-1 (HIF-1 )-deficient tumors, which grow along pre-existing brain capillaries without inducing neovessels. Elevated levels of RGS-5 in pericytes are also observed during wound healing and ovulation indicating a strong correlation between RGS-5 expression and active vessel remodeling beyond tumor angiogenesis.
Introduction
Neovascularization is a fundamental process that ensures adequate metabolic supply to tissues in numerous biological and pathological states, including tumorigenesis. It is tightly regulated during embryogenesis, leading to the establishment of a hierarchical vascular network. In contrast to the high proliferative activity in the prenatal stage, the vasculature in the adult is relatively quiescent. 1, 2 Exceptions are phases of active vessel remodeling in female reproductive organs and the formation of granulation tissue during wound healing. The earliest stages of angiogenesis are defined by vasodilation and increased vascular permeability of capillaries or postcapillary venules in response to proangiogenic factors such as vascular endothelial growth factor (VEGF). 3, 4 This is accompanied by detachment of support cells (pericytes) from the vessel wall and basement membrane, and extracellular matrix degradation. The underlying endothelial cells then migrate into the perivascular space, multiply and form new vascular sprouts. Pericytes are again recruited to the vasculature in response to growth factors such as platelet derived growth factor-B (PDGF-B), and in turn, reduce endothelial cell proliferation and help to mature and stabilize the newly formed vessels. 5 Angiogenesis is also a discrete and essential step during tumor formation and progression, 6 but here, the quiescent microvasculature undergoes an "angiogenic switch" and is converted into a chaotic network of proliferating tumor vessels. In contrast to physiological angiogenesis, in which new vessels rapidly mature and become stable, tumors have lost the control mechanisms to terminate vessel growth. Consequently, the tumor vasculature develops unique characteristics and becomes distinct from the normal blood supply system. Tumor vessels are not organized into the definitive venules, arterioles and capillaries of their normal counterparts, but instead, share chaotic features of all of them. Furthermore, they are dilated and tortuous, often leading to hemorrhages. Due to the constant vascular remodeling, pericytes, which are usually in close contact with the endothelium, become more loosely associated or less abundant. 7, 8 In addition to such morphological changes, tumor endothelial cells have been shown to express genes
For personal use only. on April 10, 2017 . by guest www.bloodjournal.org From   4 and surface markers that are selective for angiogenic blood vessels, supporting the notion that these endothelial cells change to become distinct from normal endothelium. [9] [10] [11] To understand the progressive angiogenic alterations leading to the profound differences in tumour vasculature, we have employed a mouse model of pancreatic islet carcinogenesis in which the "angiogenic switch" is a discrete step in tumorigenesis and occurs prior to tumor formation. 12 In RIP1-Tag5 transgenic mice, the oncogene SV40 Large T antigen (Tag) is expressed under the control of the rat insulin promoter (RIP) in cells of the pancreas when mice are approximately 10 weeks of age. 13 Consequently, transgenic mice develop islet carcinomas in a multistep pathway beginning with hyperplastic islets at about 14 weeks of age. A subset of these hyperplastic islets develops an angiogenic phenotype by the age of 16 weeks and progresses into highly vascularized, solid tumors over a period of 15 weeks. Strikingly, transformation of the microangioarchitecture, predominantly vessel dilatation, becomes apparent in hyperplastic/early angiogenic islets prior to the expansion of the tumor mass. This first phase of neovascularization is then followed by extensive vessel sprouting and total loss of vessel hierarchy in angiogenic islets, and hemorrhaging in end-stage tumors. 3 Although we have a reasonable understanding of vessel remodeling during tumor progression, and can arrest tumorigenesis by interfering with angiogenesis in RIP-Tag mice, 14, 15 it remains unclear which molecular changes in the vasculature are associated with tumor progression or regression during therapy.
In the course of characterizing the vasculature of progressively growing tumors at a molecular level, we defined markers that were associated with the angiogenic phenotype in RIP1-Tag5 mice. One of these marker genes is a member of the regulator of G-protein signaling family, 17 Therefore, RGS-5 is the first gene described which is upregulated in pericytes in vivo during the early phases of physiological and pathological neovascularization.
Methods

Mice
RIP1-Tag5 mice (kindly provided by D. Hanahan) were generated in the C3HeB/Fe background.
In these transgenic mice expression of the Tag oncogene in pancreatic islets starts at approximately week 10 and leads to premature death between week 30 to 35. C3HeB/Fe wildtype mice were used to study ovarian angiogenesis and wound healing. Generation of hypoxia-inducible factor-1 (HIF-1 ) wildtype and HIF-1 knock-out astrocytomas and intracranial implantation into athymic mice has been published previously. 18 Irradiation of RIP1-Tag5 mice, bone marrow reconstitution and adoptive transfers have been described. 15 All mice in the treatment group received 3 adoptive transfers with CD4 + Tag-specific effector cells (TagTCR1). After therapy, tumor nodules with a 'white' appearance were isolated from pancreatic tissue and compared to "red" tumors in untreated RIP1-Tag5 mice. The mouse hypoxanthine phosphoribosyltransferase (HPRT) gene served as an internal standard.
The following mouse-specific primers (5' to 3') were used: CD146:
CACGACATTGGCTTGAATAGTTG, CACGTCACTCCCCATGATGA; Claudin-5:
GCCCAGCTCGTACTTCTGTGA, TTAAGGCACGGGTAGCACTCA; Desmin: GATGCAGGAAACTACACGGTCAT, GGTCCCATACTGGTAGGAATCCA.
Immunohistochemistry
Tissue was freshly frozen in OCT compound (Tissue Tek, Vogel, Germany). Alternatively, mice were heart-perfused with PBS and 4% paraformaldehyde, and organs were immerged in 30% sucrose overnight. Pre-fixed tissue was then frozen in OCT compound. Staining was performed as described 13 on 7-10 µm sections with anti-CD31 (rat IgG2a, MEC 13.3, BD Pharmingen, Heidelberg, 5 µg/ml), followed by Cy3-conjugated IgG F(ab')2 fragment goat anti-rat (Dianova, Hamburg, 3 µg/ml) as secondary reagent. Stainings for anti-desmin (mouse IgG1, D33, Dako, Hamburg, 1:300) and anti-PDGFR (mouse IgG2a, 28D4, BD Pharmingen, 10 µg/ml) were performed using the FITC-M.O.M. kit (Vector, Alexis, Grünberg). Tissues were covered with Vectashield mounting medium containing dapi (Vector). All histology was analyzed using the Axioplan 2 microscope (Carl Zeiss GmBH, Hallbergmoos). AxioCAM camera and AxioVision 3.1 (Zeiss) were used for image recording. All images were processed using Adobe Photoshop software. 
FACS sorting
Preparation of single cell suspensions from solid RIPTag tumors has been described previously. 17 Briefly, isolated tumors from 5 to 7 30-week-old RIP1-Tag5 mice were minced with a razor blade and digested in a 20 ml cocktail of 1 x PBS containing 10 mg/ml BSA, 550 U/ml Collagenase II (Worthington, Cell Systems Biotechnoloy, St. Katharinen), 500 U/ml Collagenase IV (Worthington) and 3 U/ml Dnase I (Worthington) for 15 min in a 37 °C waterbath equipped with a submersible stirrer. Digestion was stopped by adding DMEM/5% FCS. Cells were passed through a 70 µm cell strainer and washed at 720 g for 5 min. Erythrocytes were then lysed in 1 ml PharmLyse buffer for 20 s (BD Pharmingen) and washed in DMEM/5% FCS. The single cell suspension was incubated with Fc block (CD16/CD32, 2.4G2, BD Pharmingen, 2.5 µg/µl) prior to specific staining. For the isolation of endothelial cells, tumor cells were stained with anti-CD31-PE (rat IgG2a, MEC 13.3, BD Pharmingen, Heidelberg, 4 µg/ml) and ME-9F1-FITC (rat IgG2a, kindly provided by A. Hamann, 30 µg/ml). For the isolation of perivascular cells, tumor cells were incubated with anti-CD140b (rat IgG, e-bioscience, THP Medical Products, Vienna, Austria, 30 µg/ml) which was APC-labeled with the Phycolink Allophycocyanin Conjugation Kit (Prozyme, 10 Europa Bioproducts, Ely, UK). Propidium iodine (1µg/ml) was added for the exclusion of dead cells. Cells were sorted using a FACSVantage SE flow cytometer.
Skin Wounds
Wounds of about 5 mm in length were introduced on the back of C3HeB/Fe mice by cutting the skin and panniculus carnosus. At 1, 3, 6, 9 and 14 days after wounding, 5 to 9 skin samples per group were harvested. The complete wound including 2 mm of the margins was excised at each time point. A similar amount of skin from untreated animals was collected. Tissue was snap frozen in liquid nitrogen for RNA analysis.
Isolation of pancreatic normal islets, angiogenic islets and solid tumors
After retrograde perfusion with 1 x Hanks Balanced Salt Solution (Invitrogen)/25 mM Hepes (pH 7.4), tissue was excised and four pancreata digested in 13 ml 1 x Hanks/Hepes containing Collagenase type XI (Sigma, 1200 U/ml) for 12 min at 37 °C. Collagenase digestion was terminated by washing cells twice in ice-cold 1 x Hanks/Hepes/1% BSA. Cells were resuspended in 27% Ficoll (Sigma) in 1 x Hanks/0.1% BSA and overlaid by 23% and 11% Ficoll solutions.
Islets were enriched in the first and second interphase after 20 min centrifugation at 800g. Single islets were isolated under a dissecting microscope. Angiogenic islets can be discriminated from normal pancreatic islets by size and the appearance of red patches due to neovascularization and hemorrhaging. Solid tumors were dissected from pancreatic tissue with scissors.
Western Blotting
Protein extracts from isolated islets of Langerhans and dissected tumors were prepared as described. 13 20 µl of protein extracts were separated on 10 % SDS/PAGE, blotted and incubated with anti-PDGFR-(rabbit polyclonal, BD Pharmingen,1:500), anti-VEGFR2 (rat IgG2a, Avas12a1, BD Pharmingen, 1 µg/ml) and anti-GAPDH (IgG1, Chemicon International, Hofheim, 3.3 µg/ml), followed by horseradish peroxidase-labeled secondary antibodies (10 ng/ml, Vector, Alexis) and Super Signal chemiluminescent substrate (Pierce, Rockford, IL).
Results
RGS-5 Upregulation in RIP1-Tag5 Tumors Coincides with the "Angiogenic Switch"
Using a differential cDNA cloning approach between blood vessels of normal islets of Langerhans and pancreatic tumors of RIP1-Tag5 mice, we found RGS-5, a known member of a larger family of regulators of G-protein signaling, to be highly upregulated in tumors (unpublished results).
Northern blot (Fig. 1 A) and quantitative RT-PCR ( Fig. 1 B) analyses showed that RGS-5 transcription was induced 4-to 5-fold in pancreatic islet tumors when compared to normal pancreas, which exhibited very low levels of RGS-5 RNA. This is in agreement with the finding that RGS-5 is constitutively expressed in a variety of murine organs, specifically in brain but also in heart, aorta, skeletal muscle, liver and kidney. 20 To define the cell source and the onset of RGS-5 transcription, we performed in situ hybridization analyses on transgenic pancreatic tissues of 25-30 week-old RIP1Tag5 mice, which display all stages of tumor progression. We found RGS-5 staining in cells that are closely associated with tumor blood vessels (Fig. 2 A) , confirming our initial findings using the differential cDNA cloning approach. RGS-5 signals were not detectable 12 in normal and hyperplastic islets or in the adjacent exocrine pancreas of transgenic mice ( Fig. 2 B and C). However, we observed spotty RGS-5 staining in a subset of early angiogenic islets (Fig. 2   D) that are characterized by the first appearance of dilated blood vessels as we have previously shown with intravital microscopy. 3 This stage is defined as the "angiogenic switch" 21 . Larger and more advanced angiogenic islets displayed a further increase in the number of RGS-5 positive cells in close conjunction to vessels (Fig. 2 E) . The most dominant expression of RGS-5, however, was detected in small and large vessels of late-stage tumors (Fig. 2 F) . Thus, RGS-5 upregulation coincides with the "angiogenic switch" in vessel-associated cells and increases during tumor progression, exhibiting highest levels in solid, end-stage tumors. For 
angiogenic islets (E, 10x) and highly vascularized, solid tumors (F, 5x). Tumor vessels (arrows) can be distinguished from "blood lakes" (arrowheads), tumor cell-lined caveties, which do not participate in the blood circulation. Dotted lines indicate islet boundaries.
RGS-5 is Induced in Physiological Angiogenesis
In order to reveal whether RGS-5 is also upregulated in physiological angiogenesis, we monitored RGS-5 expression in hormone-induced ovarian angiogenesis 22 and in granulation tissue of cutaneous wounds. 23 Fig. 3 A depicts the histology of a mouse ovary after hormone-induced ovulation in which follicles of different maturation stages are surrounded by the highly vascularized ovarian stroma. In situ hybridization analysis displayed strong RGS-5 expression in close association with blood vessels (Fig. 3 B) . In skin, wounds were introduced on the back of C3H mice, and skin samples collected at various time points thereafter (day 1, 3, 6, 9, 14). RGS-5 transcription levels in total RNA preparations of wounds and healthy skin were compared using quantitative RT-PCR. RGS-5 expression exactly follows the kinetics of wound healing, where granulation tissue builds up to reach a maximum at around day 6 and steadily declines thereafter (Fig. 3 C) . By day 14, most of the granulation tissue has resolved and the wounded skin is hardly discernible from undamaged skin. Thus, in cutaneous wound healing, RGS-5 expression rises due to increased neovascularization in granulation tissue.
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RGS-5 is Overexpressed in PDGFR-+ Perivascular Cells
Although we demonstrated RGS-5 mRNA expression in the lining of ovarian and tumor vessels, the close proximity of endothelial and perivascular cells makes it difficult to resolve cell-type specificity by in situ hybridization. However, since RGS-5 expression has been reported in developing pericytes in the embryo, 24, 25 we aimed to analyze RGS-5 expression separately in endothelial cells and pericytes to define its cell-type specificity. Tumors from 30-week-old RIP1-Tag5 mice were isolated and single cell suspensions were sorted by flow cytometry. Endothelial cells were discriminated by CD31 (PECAM) expression and immunoreactivity for the hybridoma ME-9F1. ME-9F1 has been described to selectively react with mouse endothelial cells. 26 
Perivascular cells were sorted as CD31 -and PDGFR-+ cells (data not shown). PDGFR-has
previously been shown to be a suitable marker for pericytes in RIP-Tag tumors and is not expressed by tumor cells. 17 To further assess specificity and purity of the sorted cell populations, quantitative RT-PCR analyses of various markers were performed. Selective expression of the known endothelial cell markers CD146, VEGFR1, VEGFR2, tie2, PDGF-B, VE-Cadherin and Claudin-5 were found in CD31/ME-9F1-positive cells, whilst the perivascular cell markers desmin and SMA were expressed in PDGFR-+ cells (Fig. 4 A) . Most interestingly, however, RGS-5 expression is dramatically upregulated in the perivascular cell population (Fig. 4 B) . Double labeling experiments using desmin as perivascular marker confirm the co-localization with RGS-5 transcripts in RT5 tumor vessels (Fig. 4 C) . In contrast, the endothelial cell marker CD31 is in close vicinity to RGS-5, but the expression does not overlap (Fig. 4 D) . To resolve this issue, we compared PDGFR-and RGS-5 expression between normal and tumor tissue. In normal islets, PDGFR-+ cells are found in the vascular network (Fig. 5 A) , whereas RGS-5 expression is absent (Fig. 5 B) . This is consistent with RGS-5 expression data shown in Fig. 2 B. In contrast, in solid tumors PDGFR-+ and RGS-5 + cells exert comparable staining patterns on consecutive sections (Fig. 5 C and D) . These findings imply that pericytes qualitatively change by upregulating RGS-5 expression during tumor progression. However, from our histological analyses (Fig. 5 A-D) we cannot exclude a simultaneous increase in pericyte numbers.
Since negative results from in situ hybridization should be interpreted with caution, we complemented our histological studies with quantitative RT-PCR analyses of RGS-5 and endothelial/pericyte markers at different tumor stages. Total RNA was prepared from separate pools of normal islets and angiogenic islets as well as from end-stage insulinomas. Surprisingly, we found that the relative expression of pericyte (PDGFR-, desmin, SMA) and endothelial (VEGFR2) markers decreases with tumor progression (Fig. 5 E) . These RNA data were confirmed in western blot analyses using PDGFR-and VEGFR2 as representative markers (Fig. 5 F) . This result implies that overall vessel density and pericyte number decrease during tumor progression.
Indeed, lower vessel density has been reported in a variety of cancers and is a function of the reduced oxygen requirement of malignant cells. 3, 18, 28 In contrast, the reciprocal, high RGS-5 expression in insulinomas (Fig. 5 G) suggests upregulated RGS-5 expression by tumor pericytes and not increased pericyte recruitment.
Differential RGS-5 Expression in Brain Tumors with High and Low Angiogenic Potential
Having demonstrated progressive RGS-5 upregulation in pericytes during the "angiogenic switch" in pancreatic islet carcinogenesis, we aimed to determine if this phenomenon also occurred in other tumor models. Interestingly, two orthotopic astrocytoma models were recently developed that differ in their ability to switch on angiogenesis. 18 Upon transplantation into mouse brain, SV40 Tag/H-ras transformed astrocytes (WT-AST) develop into hypoxic, necrotic and hemorrhagic tumors with a typical activated tumor vasculature that resembles the RIP1-Tag5 tumor phenotype. 18 Astrocytomas which are deficient in the HIF-1 gene (HIFko-AST) are, in contrast to WT-AST, unable to respond to hypoxia and do not display the typical features of tumor vessel remodeling but instead invade into the brain parenchyma. 18 This elegant system therefore allows a comparison of RGS-5 expression in strongly (WT-AST) versus weakly (HIFko-AST) angiogenic variants of the same tumor type. WT-AST expresses high levels of RGS-5 around the dilated tumor blood vessels, similar to blood vessels in RIP1-Tag5 tumors, suggesting pericyte origin (Fig. 6 A) . Indeed, RGS-5 has been reported to co-localize with pericytes in developing brain microvessels 24 and is expressed in certain areas of normal brain. 20, 29, 30 In contrast, HIFko-AST which does not induce tumor neovascularization exhibits significantly lower levels of RGS-5 ( Fig. 6 B) . HIFko-AST resembles non-angiogenic stages of tumor progression in RIP1-Tag5 mice prior to the "angiogenic switch". Thus, RGS-5 expression strongly correlates with the degree of vascular remodeling and angiogenesis in two independent tumor models.
For
RGS-5 is Downregulated During Therapeutic Tumor Regression
The strong correlation of RGS-5 expression and angiogenesis suggests that it may be used to monitor the effectiveness of anti-angiogenic therapy. However, potent anti-angiogenic drugs which induce vessel death do not allow assessment of RGS-5 expression levels. 14, 17 In contrast, our previously reported anti-tumor strategy, which combines irradiation and adoptive transfers of activated, tumor-specific lymphocytes, leads to complete tumor rejection by remodeling the vasculature into an almost normal appearance without inducing endothelial cell apoptosis. 15 (Fig. 6 C) . In contrast, treated tumors display a high vessel density with capillary-sized vessels resembling normal pancreatic vasculature (Fig. 6 D) . 15 Importantly, RGS-5 signals are significantly reduced in treated tumors, in concert with the vascular remodeling ( Fig. 6 E, F) . In situ hybridization results are supported by quantitative analyses of RGS-5 transcripts in treated and untreated tumors (Fig. 6 G) .
Thus, these data demonstrate that RGS-5 expression in pericytes is strongly associated with the complex and tightly regulated process of tumor angiogenesis, and becomes less important once the vasculature acquires a more stable, quiescent state.
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From 30 Similarly, downmodulation of RGS-5 has been found in neointimal smooth muscle cells (SMC) after bypass grafting in monkeys, a finding which associates RGS-5 with SMC pathology. 31 Its expression is also repressed in cytokine-stimulated vascular endothelial cells (HUVEC) in models for atherosclerosis 32 and capillary tube formation. 33 In contrast, RGS-5 expression is upregulated in a human neuroblastoma cell line after exposure to hydrostatic pressure. 34 Furthermore, increased expression of RGS-5 occurs in human renal cell carcinoma although the precise location within the tumor was not investigated. 35 Here, we report that murine RGS-5 is strongly overexpressed in autochthonous pancreatic insulinomas in a well-studied transgenic mouse model of tumorigenesis. Furthermore, overexpression is restricted to the tumor vasculature and most excitingly, temporally and quantitatively coincident with tumor-induced angiogenic activity, being first detected in progenitor lesions undergoing the "angiogenic switch". Therefore our data demonstrate for the first time an intimate association between RGS-5 expression and vessel remodeling during tumor-induced neovascularization.
The microvasculature is a complex system and fundamentally comprised of endothelial cells and stabilizing periendothelial cells, e.g., pericytes, which are embedded in the basal membrane of capillaries and postcapillary venules. 2 RGS-5 transcription has previously been detected in both vascular cell types, endothelial cells 30, 32 and perivascular SMC/pericytes.
24,31
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From However, the close association of these cells in the vasculature has made precise cellular localization of RGS-5 technically difficult, even in double-labeling experiments. By successfully isolating both cell types from insulinomas, we showed that RGS-5 transcripts are enriched in PDGFR-+ cells, which correspond to the perivascular cell compartment. This finding is consistent with a previous report demonstrating RGS-5 expression in pericytes in perinatal brain. 24 In that study, mice deficient in PDGF-B or PDGFR-lacked most of the pericytes in the developing blood vessels of the brain, with a corresponding absence of RGS-5 expression. 24 These results univocally demonstrate that RGS-5 is a marker for pericytes in the developing brain.
Moreover, RGS-5 expression is reminiscent of the expression pattern of PDGFR-during embryonic development, strongly suggesting a role of RGS-5 during fetal vascular maturation. 25 The data presented here complement these studies by revealing novel insights about RGS-5 in adult pathological neovascularization. Due to the high homology between RGS family members and the lack of RGS-5-specific antibodies, all in vivo studies rely on RNA expression data.
Strong RGS-5 expression is not only found during tumor angiogenesis, but also during ovarian angiogenesis. Moreover, RGS-5 mRNA is transiently upregulated in skin wounds during the formation of granulation tissue and declines upon wound closure (Fig. 3) . Co-localization of 37, 38 Phenotypic changes in perivascular cells have been reported for some tumor types, including the RIPTag model. 8, 27 Moreover, pericytes have been described as pluripotent cells, which can change appearance and marker expression upon cytokine activation. 39 Therefore, it is feasible that factors within the tumor environment induce "activated" or "immature" perivascular cells, and in turn, such phenotypic variation may result in differential sensitivity to extrinsic signals. For instance, only immature, PDGFR-+ pericytes involved in neovascularization respond to PDGF-B injection by detaching from endothelial cells, whereas mature vessels remain inert. 40 Similarly, inhibitors of PDGFR-signaling selectively target pericytes in RIPTag tumors, but have no effect on the vasculature in normal tissue. 17 It is generally accepted now that endothelial cells change their morphology and gene expression profile during tumor angiogenesis. 10, 19 However, molecular analyses have been lacking for tumor-resident pericytes. Thus, our data, for the first time, demonstrate molecular changes in perivascular cells, which are specifically induced during tumor angiogenesis and are potentially involved in regulating vascular angiogenic activity.
An understanding of the molecular mechanisms of neovascularization and the csontribution of distinct vascular cell types will be essential for the design of novel anti-angiogenic therapies.
For instance, a combined therapeutic approach interfering with VEGFR signaling on endothelial cells and PDGFR signaling on perivascular cells has been proven to be highly effective. It targets two distinct cell populations at different stages of tumor progression and thus produces synergistic effects. 17 This preclinical study also highlights the importance of pericytes in anti-cancer with anti-tumor therapy and RGS-5 expression decreases as the tumor vasculature returns to a more "normal" phenotype (Fig. 6) . We demonstrate here that vessel "normalization" is not limited to the endothelial compartment, but also includes perivascular cells as reflected in the reduction of RGS-5 expression. This finding has direct clinical application. There is growing evidence that "normalization" of tumor vessels will be an essential part of a new generation of combination therapies, 15, 41 and RGS-5 might be indicative of a window where intratumoral pericytes are responsive to therapy. Furthermore, elucidating the function of RGS-5 in pericyte pathobiology will not only lend important insights into tumor angiogenesis, but RGS-5 itself may also become a new target for anti-angiogenic drug development.
